Decoy Therapeutics (DCOY) Director Tess Burleson Receives 2,000-Share Award

What Happened
Tess Burleson, a director of Decoy Therapeutics Inc. (DCOY), was granted 2,000 restricted shares on August 31, 2026. The Form 4 reports an acquisition (award) of 2,000 shares at $0.00 per share (reported value $0). This was a compensation grant under the company's equity plan rather than an open-market purchase or sale.

Key Details

• Transaction date: August 31, 2026; Form 4 filed September 2, 2026.
• Transaction type/code: Award/grant (A). Reported price: $0.00; reported value: $0.
• Vesting: The shares are restricted stock under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan and will vest 100% on August 30, 2027. (Footnote F1)
• Shares owned after transaction: The filing does not state a specific post-transaction total; it notes holdings have been adjusted to reflect reverse stock splits effective August 15, 2025 and March 6, 2026. (Footnote F2)
• Timing: Filing shows report date Sept 2, 2026; the Form 4 lists the transaction date as Aug 31, 2026 (no late-filing indication in the document).

Context
Restricted stock awards to directors are common compensation and do not by themselves indicate buying or selling sentiment. Because these shares vest in the future (100% vesting on Aug 30, 2027), they are intended as retention/compensation and are not immediately liquid. Retail investors often pay more attention to open-market purchases or sales for near-term insider sentiment; grants are primarily informative about compensation and alignment with shareholders.